CJC-1295 NO DAC 5mg

CJC-1295 NO DAC is a research peptide designed for scientific investigation into growth hormone secretion and metabolic processes. This 5mg vial contains lyophilized peptide powder suitable for laboratory use and study protocols. CJC-1295 without DAC (Drug Affinity Complex) offers a shorter half-life compared to its DAC counterpart, making it ideal for researchers exploring acute dosing schedules and rapid pharmacokinetic profiles. The peptide works by stimulating growth hormone-releasing hormone (GHRH) pathways, providing a focused tool for investigating GH dynamics in controlled research settings. Each vial is manufactured to pharmaceutical-grade standards and supplied as a stable, freeze-dried powder. Reconstitution with bacteriostatic water is recommended for storage and handling. Suitable for qualified researchers and institutions conducting peptide research.

Peptide Sequence: GHRH analog (modified) Molecular Weight: 2094.24 g/mol Purity: ≥98% (HPLC) Form: Lyophilized powder Vial Size: 5mg per vial Appearance: White to off-white lyophilized cake Storage: 2–8°C (refrigerated) or -20°C (long-term) Reconstitution: Bacteriostatic water (0.9% benzyl alcohol in saline) Half-life: 30 minutes (without DAC) Mechanism: GHRH receptor agonist Research Applications: GH secretion studies, metabolic research, pharmacokinetic investigations Stability: Stable when properly reconstituted and stored Intended Use: Research and laboratory use only Packaging: Sterile vial with flip-top cap

Molecular Formula: C152H252N44O42

Storage Before Reconstitution (Lyophilized Powder): Store in original vial at 2–8°C (refrigerated) for short-term use (up to 3 months). For long-term storage, keep at -20°C or below for up to 12 months. Protect from light and moisture. Keep vial sealed until ready for use. Avoid repeated freeze-thaw cycles. Storage After Reconstitution (Solution): Reconstituted solution should be stored at 2–8°C (refrigerated). Typical stability: 3–7 days when reconstituted with bacteriostatic water. Use sterile technique during reconstitution to maintain sterility. Store in sterile vials with appropriate sealing. Do not freeze reconstituted solution unless specifically required for your protocol. Discard any unused reconstituted solution after the recommended storage period.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. GHRH Receptor Cloning and Agonist Binding
   Mayo KE, et al. (1992). Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular Endocrinology, 6(10), 1734–1744. https://doi.org/10.1210/mend.6.10.1333056
   Reports the cloning and characterisation of the GHRH receptor (GHRHR), establishing the molecular target through which CJC-1295 (no DAC) exerts its GH-releasing effects and providing structural context for GHRH receptor agonist research.
2. CJC-1295 Pharmacokinetics: DAC vs. No-DAC Comparison
   Jetté L, et al. (2005). hGRF1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: A Comparison of the Pharmacokinetics and Pharmacodynamics of Eight Bioconjugates. Journal of Pharmacology and Experimental Therapeutics, 317(3), 1228–1237. https://doi.org/10.1124/jpet.105.089755
   Directly compares GHRH analogues with and without albumin-binding modifications, providing the key pharmacokinetic reference for the shorter half-life (~30 minutes) and pulsatile GH release pattern characteristic of the no-DAC form.
3. Pulsatile GH Release and Physiological Relevance
   Giustina A & Veldhuis JD. (1998). Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews, 19(6), 717–797. https://doi.org/10.1210/edrv.19.6.0353
   Comprehensive review of the neuroendocrine regulation of pulsatile GH secretion, providing essential physiological context for research using short-acting GHRH analogues such as CJC-1295 (no DAC) to model endogenous GH pulse dynamics.
4. CJC-1295 Clinical Pharmacodynamics
   Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
   Provides critical comparative pharmacodynamic data; the sustained GH/IGF-1 elevation observed with the DAC form contrasts directly with the acute, pulsatile profile of CJC-1295 (no DAC), making this an essential reference for researchers designing short-acting GHRH protocol studies.
5. GHRH Analogues in Metabolic Research
   Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
   Investigates the metabolic effects of a GHRH(1–29) analogue in a clinical research setting, demonstrating changes in body composition and lipid metabolism — providing relevant context for researchers studying the downstream metabolic consequences of GHRH receptor activation.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.